Targeted DNA demethylation of the Fgf21 promoter by CRISPR/dCas9-mediated epigenome editing.
Nozomi HanzawaKoshi HashimotoXunmei YuanKenichi KawahoriKazutaka TsujimotoMiho HamaguchiToshiya TanakaYuya NagaokaHiroshi NishinaSumiyo MoritaIzuho HatadaTetsuya YamadaYoshihiro OgawaPublished in: Scientific reports (2020)
Recently, we reported PPARα-dependent DNA demethylation of the Fgf21 promoter in the postnatal mouse liver, where reduced DNA methylation is associated with enhanced gene expression after PPARα activation. However, there is no direct evidence for the effect of site-specific DNA methylation on gene expression. We employed the dCas9-SunTag and single-chain variable fragment (scFv)-TET1 catalytic domain (TET1CD) system to induce targeted DNA methylation of the Fgf21 promoter both in vitro and in vivo. We succeeded in targeted DNA demethylation of the Fgf 21 promoter both in Hepa1-6 cells and PPARα-deficient mice, with increased gene expression response to PPARα synthetic ligand administration and fasting, respectively. This study provides direct evidence that the DNA methylation status of a particular gene may determine the magnitude of the gene expression response to activation cues.
Keyphrases
- dna methylation
- gene expression
- genome wide
- insulin resistance
- circulating tumor
- copy number
- single molecule
- crispr cas
- cell free
- cancer therapy
- induced apoptosis
- preterm infants
- fatty acid
- cell cycle arrest
- oxidative stress
- drug delivery
- blood pressure
- metabolic syndrome
- signaling pathway
- blood glucose
- genome editing
- adipose tissue
- nucleic acid
- circulating tumor cells
- endoplasmic reticulum stress
- pi k akt